Zielgerichtete Radionuklidtherapie zur Therapie ossärer Metastasen

Im multimodalen Therapiekonzept ossärer Metastasen und der Schmerzpalliation stellen die verschiedenen Optionen der Radionuklidtherapie einen wichtigen Baustein dar. Wir geben einen Überblick zum Einsatz knochengängiger Radionuklide.

• Literatur

• 1 Macedo F. et al. Bone Metastases: An Overview. Oncol Rev 2017; 11: 321
• 2 Lewington VJ. et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991; 27: 954-958
• 3 Sartor O. et al. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 2007; 109: 637-643
• 4 Parker C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-223
• 5 Gill MR. et al. Targeted radionuclide therapy in combined-modality regimens. Lancet Oncol 2017; 18: e414-e423
• 6 Ogawa K, Ishizaki A. Well-designed bone-seeking radiolabeled compounds for diagnosis and therapy of bone metastases. Biomed Res Int 2015; 2015: 676053
• 7 Ahmadzadehfar H. et al. Radionuclide Therapy for Bone Metastases: Utility of Scintigraphy and PET Imaging for Treatment Planning. PET Clin 2018; 13: 491-503
• 8 Silberstein EB, Elgazzar AH, Kapilivsky A. Phosphorus-32 radiopharmaceuticals for the treatment of painful osseous metastases. Semin Nucl Med 1992; 22: 17-27
• 9 Robinson RG. et al. Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 1995; 274: 420-424
• 10 Palmedo H. et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 2003; 21: 2869-2875
• 11 Biersack HJ. et al. Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med 2011; 52: 1721-1726
• 12 Sinzinger H, Weiss K, Hiltunen J. Background, reasons and benefits using the vienna protocol for the treatment of painful bone recurrences with 153Samarium-EDTMP. Anticancer Res 2009; 29: 3393-3395
• 13 Yuan J. et al. Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study. Clin Nucl Med 2013; 38: 88-92
• 14 Agarwal KK. et al. (177)Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study. Eur J Nucl Med Mol Imaging 2015; 42: 79-88
• 15 Saad F. et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol 2016; 17: 1306-1316